PCa Commentary #154- TREATMENT INDUCED NEUROENDOCRINE PROSTATE CANCER- Tough to Diagnose and Tough to Treat: A Primer but Concluding with a Review of a New Study Offering Hope.

by Dr. Ed Weber | Jun 30, 2021 | PCa Commentary

Neuroendocrine Prostate Cancer: What is it?  Under the sustained and intense suppression of testosterone with Lupron or Degarelix – and now with the even stronger suppression with drugs like Xtandi and Zytiga, prostatic adenocarcinoma may undergo a...

PCa Commentary #153: PSMA Targeted Radioligand Therapy for Metastatic Prostate Cancer: Where We Currently Stand and Where Research is Heading

by Dr. Ed Weber | May 28, 2021 | PCa Commentary

Radioligand Therapy (RLT) targeted with the radionuclide Lutetium 177 or Actinium 225 has been found in early studies to be promising, safe and effective. A Gestault of results has generally shown about a 50% PSA decline in 50% of patients and a median...

PCa Commentary #152: Genomic Sequencing and Genomic Classifiers: Aids to Decision Making. A primer just to provide a ‘heads-up’.

by Dr. Ed Weber | Apr 13, 2021 | PCa Commentary

Genomic classifier panels for risk stratification and whole-genome sequencing in search of actionable mutations both provide personal molecular data that can guide management decisions. However, each provides an entirely different category of information. Both are...

PCa Commentary #151: OLIGOMETASTATIC PROSTATE CANCER: Metastases Directed Therapy – Patient Selection, Imaging and Outcomes

by Dr. Ed Weber | Mar 25, 2021 | PCa Commentary

Metastases Directed Therapy (MDT) has become a realistic option for men who develop metastases after primary therapy. The theoretical foundation of MDT was succinctly stated by David Palma, M.D., PhD:             “The oligometastatic paradigm hypothesizes that...

PCa Commentary #150 – Bone Health: An Important Issue Insufficiently Acknowledged for Men on Androgen Suppression

by Dr. Ed Weber | Feb 25, 2021 | PCa Commentary

A Commentary discussing bone health and bone protective therapy may not be as eye-catching as new developments in PSMA and Axumin imaging or radioligand therapy with Lu-177, but as the old spiritual says:    “dem bones, dem bones gonna walk around …”  and we...